title: Clinically mild encephalitis/encephalopathy with a reversible splenial lesion.
abstract: OBJECTIVE
  To clarify whether patients with clinical diagnoses of encephalitis/encephalopathy with a reversible lesion in the splenium of the corpus callosum (SCC) share common clinical features.
  
  
  METHODS
  Possible encephalitis/encephalopathy patients with a reversible isolated SCC lesion on MRI were collected retrospectively. Their clinical, laboratory, and radiologic data were reviewed.
  
  
  RESULTS
  Fifteen encephalitis/encephalopathy patients with a reversible isolated SCC lesion were identified among 22 patients referred for this study. All 15 patients had relatively mild clinical courses. Twelve of the 15 patients had disorders of consciousness. Eight patients had seizures, and three of them received antiepileptic drugs. All 15 patients clinically recovered completely within 1 month (8 patients within a week) after the onset of neurologic symptoms. The SCC lesion was ovoid in six patients; it extended irregularly from the center to the lateral portion of SCC in the other eight patients. Homogeneously reduced diffusion was seen in all seven patients who underwent diffusion-weighted imaging. There was no enhancement in the five patients so examined. The SCC lesion had completely disappeared in all patients at follow-up MRI exams between 3 days and 2 months after the initial MRI (within 1 week in eight patients).
  
  
  CONCLUSIONS
  The clinical features among the affected patients were nearly identical, consisting of relatively mild CNS manifestations and complete recovery within 1 month.
authors.affiliation: Department of Pediatrics, Graduate School of Medicine, Chiba University, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tada
authors.forename: J
authors.initials: J
authors.lastname: Takanashi
authors.forename: A J
authors.initials: AJ
authors.lastname: Barkovich
authors.forename: H
authors.initials: H
authors.lastname: Oba
authors.forename: M
authors.initials: M
authors.lastname: Maeda
authors.forename: H
authors.initials: H
authors.lastname: Tsukahara
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Shimono
authors.forename: T
authors.initials: T
authors.lastname: Ichiyama
authors.forename: T
authors.initials: T
authors.lastname: Taoka
authors.forename: O
authors.initials: O
authors.lastname: Sohma
authors.forename: H
authors.initials: H
authors.lastname: Yoshikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kohno
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D001927:Brain Diseases / Q000150:complications / Q000453:epidemiology* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003244:Consciousness Disorders / Q000453:epidemiology / Q000209:etiology*; D003337:Corpus Callosum / Q000473:pathology*; D038524:Diffusion Magnetic Resonance Imaging; D004660:Encephalitis / Q000150:complications / Q000453:epidemiology* / Q000473:pathology; D018792:Encephalitis, Viral / Q000150:complications / Q000453:epidemiology / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008590:Meningoencephalitis / Q000150:complications / Q000453:epidemiology / Q000473:pathology; D008875:Middle Aged; D012075:Remission, Spontaneous; D012640:Seizures / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*
chemical_list: D000927:Anticonvulsants